Understanding how normal skin cells change to melanoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify the molecular profiles that characterize the transition from benign nevi to malignant melanoma in children and young adults with large congenital melanocytic nevi. It will longitudinally analyze cell-free DNA from participants and utilize advanced techniques such as methylomics and single-cell multi-omics to explore the cellular changes involved in this progression. The study seeks to improve early diagnosis and treatment strategies for intermediate conditions through evidence-based risk assessment and pre-clinical modeling. By integrating various genomic and transcriptomic data, the research aims to provide insights into the molecular mechanisms underlying melanoma development.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Congenital nevus with estimated size of 20 cm
* Be over 18 years of age

Exclusion criteria:

* No available biological material
* Not having signed the informed consent

Where it's running

• French National Institute of Health and Medical Research
  Marseille, France Recruiting
• Hospital Clínic de Barcelona (Dermatology service)
  Barcelona, Spain Recruiting

Study contacts

• Study coordinator: Susana Puig Sardà, MD, PhD
• Email: spuig@clinic.cat
• Phone: +34932275400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Assessing the safety and effectiveness of ENV-501 in patients with HER3-expressing solid tumors

  This study is testing a new treatment called ENV-501 to see if it is safe and effective for people with advanced solid tumors that express HER3, like melanoma, lung cancer, and breast cancer.

  Recruiting at 5 sites Phase 1/2 Hummingbird Bioscience · La Jolla, California and 6 other locations · NCT06956690

• Assessing a test to predict treatment response in advanced melanoma patients

  This study tests if the IOpener® melanoma test can help predict how well treatment will work for people with advanced melanoma who are starting their first-line therapy.

  Recruiting at 3 sites Pamgene International B.V. · Tübingen, Baden-Wurttemberg and 2 other locations · NCT06784778

• Monitoring the effects of encorafenib and binimetinib in melanoma treatment

  This study is testing how the levels of two melanoma drugs, encorafenib and binimetinib, affect side effects and treatment success in adults with a specific type of advanced melanoma.

  Recruiting Assistance Publique - Hôpitaux de Paris · Boulogne-Billancourt · NCT06774989

• Using Cyclophosphamide and Pembrolizumab for advanced melanoma treatment

  This study is testing if a combination of Cyclophosphamide and Pembrolizumab can help people with advanced melanoma who haven't responded to other treatments feel better and improve their health.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06771544

• Skipping full lymph node removal for stage III melanoma patients who show a strong response in the index node

  This trial will see if patients with resectable stage III melanoma who get neoadjuvant ipilimumab plus nivolumab and show a major pathological response in the index lymph node can safely avoid therapeutic lymph node dissection.

  Recruiting Erasmus Medical Center · Rotterdam, South Holland · NCT06754904

• Evaluating the DermaSensor device for detecting melanoma

  This study is testing a new device to see if it can accurately detect skin lesions that might be melanoma in people aged 40 and older.

  Recruiting at 2 sites DermaSensor, Inc. · New Smyrna Beach, Florida and 1 other locations · NCT06666790

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.